Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424131 | 0.90 | MGLL (0.48) | KMT2ALMNAGPR119HDAC4MGLL | |
| SCHEMBL2343318 | 0.88 | KMT2A (0.51) | KMT2ALMNAGPR119KDM4EMEN1 | |
| SCHEMBL3353056 | 0.87 | KMT2A (0.50) | KMT2ALMNAKDM4EMEN1TSHR | |
| SCHEMBL3353050 | 0.87 | KMT2A (0.50) | KMT2ALMNAKDM4EMEN1TSHR | |
| SCHEMBL2427378 | 0.80 | KMT2A (0.44) | KMT2ALMNAKDM4EMEN1TSHR | |
| SCHEMBL2432969 | 0.80 | KMT2A (0.44) | KMT2ALMNAKDM4EMEN1TSHR | |
| SCHEMBL2424231 | 0.79 | KMT2A (0.43) | KMT2ALMNAKDM4EMEN1TSHR | |
| SCHEMBL3347845 | 0.78 | MGLL (0.47) | KMT2ALMNAMGLLUSP30 | |
| SCHEMBL3347840 | 0.78 | MGLL (0.47) | KMT2ALMNAMGLLUSP30 | |
| SCHEMBL2427031 | 0.77 | MGLL (0.57) | MGLLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | KMT2A 1419/4885LMNA 3357/4885GPR119 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.